PRME:ARCA-First Trust Heitman Global Prime Real Estate (USD)

ETF | Biotechnology | NYSE Arca

Last Closing

USD 1.79

Change

0.00 (0.00)%

Market Cap

USD 0.96M

Volume

0.88M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks to provide long-term total return. Under normal market conditions, the fund will seek to achieve its investment objective by investing at least 80% of its net assets (including investment borrowings) in U.S. and non-U.S. exchange-traded real estate securities, which includes real estate investment trusts ("REITs"), real estate operating companies ("REOCs") and common stocks or depositary receipts of companies primarily engaged in the real estate industry (collectively, "RealEstate Securities"). It is non-diversified.

Inception Date: 11/11/2015

Primary Benchmark: FTSE EPRA Nareit Developed TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: NA%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-16 )

Largest Industry Peers for Biotechnology

Symbol Name Mer Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc 0.00 %

+8.99 (+1.78%)

USD 123.21B
REGN Regeneron Pharmaceuticals Inc 0.00 %

+11.55 (+1.73%)

USD 76.39B
ARGX argenx NV ADR 0.00 %

+9.23 (+1.53%)

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc 0.00 %

+11.35 (+4.69%)

USD 31.94B
ONC BeiGene, Ltd. 0.00 %

+5.88 (+2.27%)

USD 28.70B
RPRX Royalty Pharma Plc 0.00 %

+0.25 (+0.76%)

USD 18.65B
SMMT Summit Therapeutics PLC 0.00 %

-0.66 (-3.17%)

USD 17.01B
UTHR United Therapeutics Corporatio.. 0.00 %

+15.70 (+5.11%)

USD 14.37B
INCY Incyte Corporation 0.00 %

-5.85 (-8.62%)

USD 14.22B
MRNA Moderna Inc 0.00 %

+0.09 (+0.26%)

USD 13.74B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.70% 21% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.70% 21% F 13% F
Trailing 12 Months  
Capital Gain -75.00% 24% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.00% 24% F 10% F
Trailing 5 Years  
Capital Gain -91.15% 28% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -91.15% 28% F 8% B-
Average Annual (5 Year Horizon)  
Capital Gain -26.33% 17% F 9% A-
Dividend Return -26.33% 17% F 9% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.69% 91% A- 67% D+
Risk Adjusted Return -98.66% 7% C- 4% F
Market Capitalization 0.96M N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.